Cancer has a major impact on society in the United States and across the world. According to WHO’s report, the global cancer burden is estimated to have risen to 18.1 million new cases and 9.6 million deaths in 2018. One in 5 men and one in 6 women worldwide develop cancer during their lifetime, and one in 8 men and one in 11 women die from the disease.

So many families are being destroyed every year by this illness, are we ever going to find a cure for cancer?  Well, Israeli scientists say they will cure cancer within a year.

“We believe we will offer in a year’s time a complete cure for cancer,” said Dan Aridor, of a new treatment being developed by his company, Accelerated Evolution Biotechnologies Ltd. (AEBi), which was founded in 2000 in the ITEK incubator. AEBi developed the SoAP platform, which provides functional leads to very difficult targets.

Dan Aridor also said:

“Our cancer cure will be effective from day one, will last a duration of a few weeks and will have no or minimal side-effects at a much lower cost than most other treatments on the market. Our solution will be both generic and personal.

According to Dan, the treatment would not be affected by mutations; cancer cells can mutate in such a way that targeted receptors are dropped by the cancer. He also believes that the treatment will eventually be personalized, and patients would receive a specific molecule cocktail needed for an effective treatment.

Still scepticism was high among those in the know. Weighing in on behalf of the American Cancer Society (ACS) on his blog, “A Cure For Cancer? Not So Fast,” Len Lichtenfeld, MD, ACS chief medical officer cautioned: “…it goes without saying, we all share the aspirational hope that they are correct. Unfortunately, we must be aware that this is far from proven as an effective treatment for people with cancer, let alone a cure.”

Len Lichterfield went on to list several key points that should be taken into consideration:

  • This is a news report based on limited information provided by researchers and a company working on this technology. It apparently has not been published in the scientific literature where it would be subject to review, support and/or criticism from knowledgeable peers.
  • My colleagues here at American Cancer Society tell me phage or peptide display techniques, while very powerful research tools for selecting high affinity binders; have had a difficult road as potential drugs. If this group is just beginning clinical trials, they may well have some difficult experiments ahead.
  • This is based on a mouse experiment which is described as “exploratory.” It appears at this point there is not a well-established program of experiments which could better define how this works—and may not work—as it moves from the laboratory bench to the clinic.
  • We all have hope that a cure for cancer can be found and found quickly. It is certainly possible this approach maybe work. However, as experience has taught us so many times, the gap from a successful mouse experiment to effective, beneficial application of exciting laboratory concepts to helping cancer patients at the bedside is in fact a long and treacherous journey, filled with unforeseen and unanticipated obstacles.
  • It will likely take some time to prove the benefit of this new approach to the treatment of cancer. And unfortunately–based on other similar claims of breakthrough technologies for the treatment of cancer–the odds are that it won’t be successful.

Will it become part of a treatment strategy for some cancers? Lacking scientific data to review, it’s doesn’t look very promising. 

Think your friends would be interested? Share this story!

Source: Forbes, Images: Sci & Tech